Pharma Declares Wishlist As Brexit Heightens UK Election Stakes
ABPI Publishes ‘Manifesto For Medicine’
Executive Summary
The UK pharma industry association has underscored the sector’s importance while outlining its demands for the country’s policy around medicines and R&D.
You may also be interested in...
UK Plans Upfront Payment Scheme To Spur Antimicrobial Development
A new UK project will look at the potential of upfront payments to encourage companies to invest in the development of new antimicrobial drugs. The scheme, developed by NICE and NHS England, will use a tailored health technology assessment approach and is seen as a possible model for other countries to emulate in the fight against antimicrobial resistance.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.